U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C23H21ClN6O3.CH4O3S
Molecular Weight 561.01
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of LOPRAZOLAM MESILATE

SMILES

CS(O)(=O)=O.CN1CCN(CC1)\C=C2/N=C3CN=C(C4=CC=CC=C4Cl)C5=C(C=CC(=C5)[N+]([O-])=O)N3C2=O

InChI

InChIKey=DDSDPQHQLNAGLJ-YEBWQKSTSA-N
InChI=1S/C23H21ClN6O3.CH4O3S/c1-27-8-10-28(11-9-27)14-19-23(31)29-20-7-6-15(30(32)33)12-17(20)22(25-13-21(29)26-19)16-4-2-3-5-18(16)24;1-5(2,3)4/h2-7,12,14H,8-11,13H2,1H3;1H3,(H,2,3,4)/b19-14-;

HIDE SMILES / InChI

Molecular Formula C23H21ClN6O3
Molecular Weight 464.904
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Molecular Formula CH4O3S
Molecular Weight 96.106
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Loprazolam is a hypnotic drug which stimulates GABA-A receptors. Due to its hypnotic activity the drug is used to treat short-term sleep disordes.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DORMONOCT

Cmax

ValueDoseCo-administeredAnalytePopulation
4.3 ng/mL
1 mg single, oral
LOPRAZOLAM plasma
Homo sapiens
4.2 ng/mL
1 mg single, oral
LOPRAZOLAM plasma
Homo sapiens
4.1 ng/mL
1 mg 1 times / day multiple, oral
LOPRAZOLAM serum
Homo sapiens
4.6 ng/mL
1 mg 1 times / day multiple, oral
LOPRAZOLAM serum
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
46.6 ng × h/mL
1 mg single, oral
LOPRAZOLAM plasma
Homo sapiens
74.5 ng × h/mL
1 mg single, oral
LOPRAZOLAM plasma
Homo sapiens
35.5 ng × h/mL
1 mg 1 times / day multiple, oral
LOPRAZOLAM serum
Homo sapiens
50 ng × h/mL
1 mg 1 times / day multiple, oral
LOPRAZOLAM serum
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
11.22 h
1 mg single, oral
LOPRAZOLAM plasma
Homo sapiens
19.77 h
1 mg single, oral
LOPRAZOLAM plasma
Homo sapiens
8 h
1 mg 1 times / day multiple, oral
LOPRAZOLAM serum
Homo sapiens
3.3 h
1 mg 1 times / day multiple, oral
LOPRAZOLAM serum
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
15%
LOPRAZOLAM plasma
Homo sapiens

Doses

AEs

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
The usual adult dose is 1 - 2 mg at bedtime.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
VKF8383J65
Record Status Validated (UNII)
Record Version